



or




or a pharmaceutically acceptable salt thereof.

23. A compound of claim 1 which is a compound of formula:




or a pharmaceutically acceptable salt thereof.

24. The compound of claim 1 which is a compound of formula:



36. Use of a compound as described in any one of claims 1-24 or a pharmaceutically acceptable salt thereof for preparing a medicament for treating hepatitis C or a hepatitis C associated disorder in an animal.
37. A compound as described in any of claims 1-24 or a pharmaceutically acceptable salt thereof for use in the prophylactic or therapeutic treatment of hepatitis C or a hepatitis C associated disorder.
38. The use of claim 36, wherein the medicament is to be administered with an interferon or pegylated interferon.
39. The use of claim 36 or 37, wherein the medicament is to be administered with ribavirin.
40. The compound of claim 37, wherein the compound is to be administered with an interferon or pegylated interferon.
41. The compound of claim 37 or 40, wherein the compound is to be administered with an ribavirin.
42. A compound of claim 1 which is a compound of formula:



43. A pharmaceutical composition comprising the compound of claim 42 and a pharmaceutically acceptable carrier.
44. The pharmaceutical composition of claim 43, further comprising a NS5B polymerase inhibitor.
45. The pharmaceutical composition of claim 43, further comprising sofosbuvir.